Format

Send to

Choose Destination
BMJ Open. 2018 Jan 23;8(1):e019060. doi: 10.1136/bmjopen-2017-019060.

Resource utilisation and costs in predementia and dementia: a systematic review protocol.

Author information

1
Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.
2
Bodleian Health Care Libraries, University of Oxford, Oxford, UK.
3
Global Head Health Economic Modelling and Methodology, Novartis Pharmaceutical AG, Basel, Switzerland.
4
Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.
5
Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neurosciences, Alzheimer Centre Limburg, Maastricht, The Netherlands.
6
Division of Neurogeriatrics, Department of Neurobiology, Care Science and Society, Karolinska Institute, Stockholm, Sweden.
7
GE Healthcare Life Sciences, Amersham, UK.
8
Value and Access, Biogen, Cambridge, Massachusetts, USA.
9
Eli Lilly and Company, Erl Wood Manor, Windlesham, UK.

Abstract

INTRODUCTION:

Dementia is the fastest growing major cause of disability globally with a mounting social and financial impact for patients and their families but also to health and social care systems. This review aims to systematically synthesise evidence on the utilisation of resources and costs incurred by patients and their caregivers and by health and social care services across the full spectrum of dementia, from its preceding preclinical stage to end of life. The main drivers of resources used and costs will also be identified.

METHODS AND ANALYSIS:

A systematic literature review was conducted in MEDLINE, EMBASE, CDSR, CENTRAL, DARE, EconLit, CEA Registry, TRIP, NHS EED, SCI, RePEc and OpenGrey between January 2000 and beginning of May 2017. Two reviewers will independently assess each study for inclusion and disagreements will be resolved by a third reviewer. Data will be extracted using a predefined data extraction form following best practice. Study quality will be assessed with the Effective Public Health Practice Project quality assessment tool. The reporting of costing methodology will be assessed using the British Medical Journal checklist. A narrative synthesis of all studies will be presented for resources used and costs incurred, by level of disease severity when available. If feasible, the data will be synthesised using appropriate statistical techniques.

ETHICS AND DISSEMINATION:

Included articles will be reviewed for an ethics statement. The findings of the review will be disseminated in a related peer-reviewed journal and presented at conferences. They will also contribute to the work developed in the Real World Outcomes across the Alzheimer's disease spectrum for better care: multi-modal data access platform (ROADMAP).

TRIAL REGISTRATION NUMBER:

CRD42017071413.

KEYWORDS:

Alzheimer’s disease; costs; dementia; resources; systematic review

PMID:
29362261
PMCID:
PMC5988053
DOI:
10.1136/bmjopen-2017-019060
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Competing interests: This SLR is being conducted as part of the ROADMAP project. ROADMAP is a consortium of academic, public sector and industry partners working collaboratively within the European Union Innovative Medicines Initiative framework. FL, HW, IG, EN, SM, KW, NR, RW, JW and AMG declare that they have no competing interests. PL is employed by, owns stock in and has stock options in Novartis Pharma AG. ERD is employed by GE Healthcare. MP is an employee of Biogen and owns stock in Biogen. She owns stock in a variety of companies that at times include other pharmaceutical and health care-related companies. ATH is an employee of Eli Lilly and Company Limited and owns stock in Eli Lilly and Company Limited. Novartis Pharma AG, GE Healthcare, Biogen and Eli Lilly and Company Limited are industry partners in the ROADMAP Project.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center